Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain

Positron emission tomography (PET) can, when used with appropriate radioligands, non-invasively generate temporal and spatial information about acute changes in brain neurotransmitter systems. We for the first time evaluate the novel 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36, for its sensitivity to detect changes in endogenous cerebral 5-HT levels, as induced by different pharmacological challenges. To enable a direct translation of PET imaging data to changes in brain 5-HT levels, we calibrated the [11C]Cimbi-36 PET signal in the pig brain by simultaneous measurements of extracellular 5-HT levels with microdialysis and [11C]Cimbi-36 PET after various acute interventions (saline, citalopram, citalopram + pindolol, fenfluramine). In a subset of pigs, para-chlorophenylalanine pretreatment was given to deplete cerebral 5-HT. The interventions increased the cerebral extracellular 5-HT levels to 2–11 times baseline, with fenfluramine being the most potent pharmacological enhancer of 5-HT release, and induced a varying degree of decline in [11C]Cimbi-36 binding in the brain, consistent with the occupancy competition model. The observed correlation between changes in the extracellular 5-HT level in the pig brain and the 5-HT2A receptor occupancy indicates that [11C]Cimbi-36 binding is sensitive to changes in endogenous 5-HT levels, although only detectable with PET when the 5-HT release is sufficiently high.

[1]  C. Repérant,et al.  Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice , 2008, Neuropharmacology.

[2]  Wolfgang Gaebel,et al.  Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man , 2003, Behavioural Brain Research.

[3]  Mark Slifstein,et al.  In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride , 2004, Synapse.

[4]  L. Cervo,et al.  Strain differences in basal and post‐citalopram extracellular 5‐HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase‐2 activity , 2007, Journal of neurochemistry.

[5]  Alan A. Wilson,et al.  First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study , 2008, Neuropsychopharmacology.

[6]  R Tao,et al.  Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  C. Svarer,et al.  No change in [11C]CUMI‐101 binding to 5‐HT1A receptors after intravenous citalopram in human , 2012, Synapse.

[8]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[9]  Anders Ettrup,et al.  Pilot study on receptor binding and serotonin sensitivity of [11C]CIMBI-36 in monkey brain , 2011 .

[10]  H. Boecker,et al.  What to learn from in vivo opioidergic brain imaging? , 2005, European journal of pain.

[11]  G. Knudsen,et al.  Central serotonin depletion affects rat brain areas differently: A qualitative and quantitative comparison between different treatment schemes , 2006, Neuroscience Letters.

[12]  A. Bauer,et al.  Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans , 2007, Journal of Neural Transmission.

[13]  N. Harada,et al.  Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [ 11 C ]raclopride?: PET studies combined with microdialysis in conscious monkeys , 1999, Brain Research.

[14]  M. Liebowitz,et al.  Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder , 2009, Depression and anxiety.

[15]  Gitte M Knudsen,et al.  Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  A. Fray,et al.  Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. , 2002, European journal of pharmacology.

[17]  Flemming Andersen,et al.  MR-Based Statistical Atlas of the Göttingen Minipig Brain , 2001, NeuroImage.

[18]  C. Montigny,et al.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.

[19]  S. Kapur,et al.  The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET , 1999, Psychopharmacology.

[20]  Flemming Andersen,et al.  Evaluation of the Novel 5-HT4 Receptor PET Ligand [11C]SB207145 in the Göttingen Minipig , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Vibe G. Frokjaer,et al.  A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation , 2009, NeuroImage.

[22]  J. B. Justice,et al.  Quantitative microdialysis of serotonin and norepinephrine: Pharmacological influences on in vivo extraction fraction , 1996, Journal of Neuroscience Methods.

[23]  R. Narendran,et al.  Imaging dopamine transmission in the frontal cortex: a simultaneous microdiaysis and [11C]FLB 457 PET study , 2013, Molecular Psychiatry.

[24]  R. Hen,et al.  Effects of chronic paroxetine treatment on dialysate serotonin in 5‐HT1B receptor knockout mice , 2003, Journal of neurochemistry.

[25]  Christer Halldin,et al.  Confirmation of Fenfluramine Effect on 5-HT1B Receptor Binding of [11C]AZ10419369 using an Equilibrium Approach , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  F. Artigas,et al.  Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. , 1992, European journal of pharmacology.

[27]  G. Knudsen,et al.  Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy , 2014 .

[28]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  René Hen,et al.  Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. , 2008, The international journal of neuropsychopharmacology.

[30]  N. Gillings.  A restricted access material for rapid analysis of [(11)C]-labeled radiopharmaceuticals and their metabolites in plasma. , 2009, Nuclear medicine and biology.

[31]  B. Hoebel,et al.  Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis , 1989, Brain Research.

[32]  F. Turkheimer,et al.  Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study , 2012, Molecular Psychiatry.

[33]  A. Bauer,et al.  Sleep deprivation increases cerebral serotonin 2A receptor binding in humans. , 2012, Sleep.

[34]  J. A. Boer,et al.  Effect of Increased Serotonin Levels on [18F]MPPF Binding in Rat Brain: Fenfluramine vs the Combination of Citalopram and Ketanserin , 2005, Neuropsychopharmacology.

[35]  Roberto Invernizzi,et al.  Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex , 1992, Brain Research.

[36]  J. B. Justice,et al.  Quantitative microdialysis under transient conditions. , 1993, Analytical chemistry.

[37]  Mark Slifstein,et al.  Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. , 2007, The American journal of psychiatry.

[38]  Mark Slifstein,et al.  Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum , 2005, Biological Psychiatry.

[39]  M. Hajós,et al.  Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT , 1995, British journal of pharmacology.

[40]  B. Laferrère,et al.  Effect of d-fenfluramine on serotonin release in brains of anaesthetized rats , 1989, Brain Research.

[41]  F. Artigas,et al.  Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  Christer Halldin,et al.  Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. , 2013, The international journal of neuropsychopharmacology.

[43]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  G. Knudsen,et al.  Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT7 Receptors , 2014, The Journal of Nuclear Medicine.

[45]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[46]  C. Svarer,et al.  Serotonin 2A Receptor Agonist Binding in the Human Brain with [11C]Cimbi-36 , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  Christer Halldin,et al.  Application of cross-species PET imaging to assess neurotransmitter release in brain , 2015, Psychopharmacology.

[48]  T. Gray,et al.  p-Chlorophenylalanine and fluoxetine inhibit d-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions , 1997, Brain Research.

[49]  Matthias M Herth,et al.  (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. , 2015, Bioorganic & medicinal chemistry letters.

[50]  M. Gobbi,et al.  In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[51]  Barry L. Jacobs,et al.  Handbook of the behavioral neurobiology of serotonin , 2010 .

[52]  P. Celada,et al.  Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/G(o) proteins in dorsal raphe nucleus. , 1994, European journal of pharmacology.

[53]  G. Knudsen,et al.  An approach for serotonin depletion in pigs: Effects on serotonin receptor binding , 2011, Synapse.

[54]  R. Summers,et al.  Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. , 1990, The Journal of pharmacology and experimental therapeutics.

[55]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Fuller.  Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. , 1994, Life sciences.

[57]  Søren Holm,et al.  [18F]altanserin Binding to Human 5HT2A Receptors is Unaltered after Citalopram and Pindolol Challenge , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  N. Harada,et al.  Effect of fenfluramine‐induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeys , 2006, Synapse.

[59]  Valerie Treyer,et al.  Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography , 2012, NeuroImage.

[60]  A. Gardier,et al.  Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. , 1995, European journal of pharmacology.